| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A dihydro-pyrido-indole potently inhibits HSV-1 infection by interfering the viral immediate early transcriptional events
|
Bag, Paromita
|
|
2014
|
105 |
C |
p. 126-134
9 p.
|
artikel
|
| 2 |
A murine model of coxsackievirus A16 infection for anti-viral evaluation
|
Liu, Qingwei
|
|
2014
|
105 |
C |
p. 26-31
6 p.
|
artikel
|
| 3 |
Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?
|
Schneider, Maximilian David
|
|
2014
|
105 |
C |
p. 64-71
8 p.
|
artikel
|
| 4 |
Are statins a viable option for the treatment of infections with the hepatitis C virus?
|
Verpaalen, Ben
|
|
2014
|
105 |
C |
p. 92-99
8 p.
|
artikel
|
| 5 |
Determining anti-betanodavirus compounds through a GF-1 cell-based screening platform
|
Huang, Yi-Cheng
|
|
2014
|
105 |
C |
p. 47-53
7 p.
|
artikel
|
| 6 |
Inhibition of replication of porcine reproductive and respiratory syndrome virus by hemin is highly dependent on heme oxygenase-1, but independent of iron in MARC-145 cells
|
Wang, Liangliang
|
|
2014
|
105 |
C |
p. 39-46
8 p.
|
artikel
|
| 7 |
Inside Back Cover: Notes to Authors
|
|
|
2014
|
105 |
C |
p. IBC-
1 p.
|
artikel
|
| 8 |
In vitro surrogate models to aid in the development of antivirals for the containment of foot-and-mouth disease outbreaks
|
Osiceanu, Ana-Maria
|
|
2014
|
105 |
C |
p. 59-63
5 p.
|
artikel
|
| 9 |
ISAR News
|
|
|
2014
|
105 |
C |
p. III-X
nvt p.
|
artikel
|
| 10 |
Monovalent H5 vaccine based on epitope-chimeric HA provides broad cross-clade protection against variant H5N1 viruses in mice
|
He, Fang
|
|
2014
|
105 |
C |
p. 143-151
9 p.
|
artikel
|
| 11 |
Nucleoside analogues alone or combined with vaccination prevent hepadnavirus viremia and induce protective immunity: Alternative strategy for hepatitis B virus post-exposure prophylaxis
|
Wang, Baoju
|
|
2014
|
105 |
C |
p. 118-125
8 p.
|
artikel
|
| 12 |
Oseltamivir–zanamivir combination therapy is not superior to zanamivir monotherapy in mice infected with influenza A(H3N2) and A(H1N1)pdm09 viruses
|
Pizzorno, Andrés
|
|
2014
|
105 |
C |
p. 54-58
5 p.
|
artikel
|
| 13 |
Peripheral blood mononuclear cells microRNA predicts treatment outcome of hepatitis C virus genotype 1 infection
|
Hsi, Edward
|
|
2014
|
105 |
C |
p. 135-142
8 p.
|
artikel
|
| 14 |
Polymerases of hepatitis C viruses and flaviviruses: Structural and mechanistic insights and drug development
|
Caillet-Saguy, Célia
|
|
2014
|
105 |
C |
p. 8-16
9 p.
|
artikel
|
| 15 |
Prelim II: Editorial Board
|
|
|
2014
|
105 |
C |
p. ii-
1 p.
|
artikel
|
| 16 |
Sublingual administration of a helper-dependent adenoviral vector expressing the codon-optimized soluble fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in mice
|
Fu, Yuan-hui
|
|
2014
|
105 |
C |
p. 72-79
8 p.
|
artikel
|
| 17 |
Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model
|
Oestereich, Lisa
|
|
2014
|
105 |
C |
p. 17-21
5 p.
|
artikel
|
| 18 |
Telaprevir or boceprevir based therapy for chronic hepatitis C infection: Development of resistance-associated variants in treatment failure
|
Macartney, Malcolm J.
|
|
2014
|
105 |
C |
p. 112-117
6 p.
|
artikel
|
| 19 |
The beginning of the end: What is the future of interferon therapy for chronic hepatitis C?
|
Feld, Jordan J.
|
|
2014
|
105 |
C |
p. 32-38
7 p.
|
artikel
|
| 20 |
The past, present and future of neutralizing antibodies for hepatitis C virus
|
Ball, Jonathan K.
|
|
2014
|
105 |
C |
p. 100-111
12 p.
|
artikel
|
| 21 |
Towards hepatitis C eradication from the HIV-infected population
|
Barreiro, Pablo
|
|
2014
|
105 |
C |
p. 1-7
7 p.
|
artikel
|
| 22 |
Treatment of norovirus infections: Moving antivirals from the bench to the bedside
|
Kaufman, Stuart S.
|
|
2014
|
105 |
C |
p. 80-91
12 p.
|
artikel
|
| 23 |
What are the pros and cons of the use of host-targeted agents against hepatitis C?
|
Pawlotsky, Jean-Michel
|
|
2014
|
105 |
C |
p. 22-25
4 p.
|
artikel
|
Tijdschrift beschrijving